Efficient bifunctional decadentate ligand 3p-C-DEPA for targeted α-radioimmunotherapy applications

Bioconjugate Chemistry

Volumn 22, Issue 6, 2011, Pages 1128-1135

  Song, Hyun A ^a   Kang, Chi Soo ^a   Baidoo, Kwamena E ^b   Milenic, Diane E ^b   Chen, Yunwei ^a   Dai, Anzhi ^a   Brechbiel, M W ^b   Chong, Hyun Soon ^a  

^a Illinois Institute of Technology   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODIES; TUMORS;

AZIRIDINIUM IONS; BI-FUNCTIONAL; BIFUNCTIONAL LIGAND; HUMAN SERUM; IN-VIVO; RADIOIMMUNOTHERAPY; REGIOSPECIFIC; RING OPENING; SYNTHESISED; TRASTUZUMAB;

LIGANDS;

3P C 1,7 [2 (BIS CARBOXYMETHYL AMINO)ETHYL] 4,10 BIS CARBOXYMETHYL 1,4,7,10 TETRAAZA CYCLODODEC 1 YL ACETIC ACID) TRASTUZUMAB CONJUGATE BI 205; 3P C 1,7 [2 (BIS CARBOXYMETHYL AMINO)ETHYL] 4,10 BIS CARBOXYMETHYL 1,4,7,10 TETRAAZA CYCLODODEC 1 YL ACETIC ACID) TRASTUZUMAB CONJUGATE BI 206; AZIRIDINE; C 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TRASTUZUMAB CONJUGATE; RADIOISOTOPE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; RADIOIMMUNOTHERAPY; RING OPENING; TUMOR XENOGRAFT;

MUS;

EID: 79959274681     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc100586y     Document Type: Article

References (27)

1. Knox, S. J. and Meredith, R. F. (2000) Clinical radioimmunotherapy Sem. Radiat. Oncol. 10, 73-93 (Pubitemid 30205489)
2. Milenic, D. E., Brady, E. D., and Brechbiel, M. W. (2004) Antibody-targeted radiation cancer therapy Nat. Rev. 3, 488-98 (Pubitemid 38807531)
3. 213Bi, and their decay chain related radionuclides for therapeutic applications Chem. Rev. 101, 2019-36 (Pubitemid 35381672)
4. Jurcic, J. G., Larson, S. M., Sgouros, G., McDevitt, M. R., Finn, R. D., Divgi, C. R., Ballangrud, A. M., Klaus, K. A., Ma, D., Humm, J. L., Brechbiel, M. W., Molinet, R., and Scheinberg, D. A. (2002) Targeted alpha particle immunotherapy for myeloid leukemia Blood 100, 1233-39 (Pubitemid 34864277)
5. Mulford, D. A., Pandit-Taskar, N., McDevitt, M. R., Finn, R. D., Weiss, M. A., Apostolidis, C., Morgenstern, A., Divgi, C. R., Larson, S. M., Scheinberg, D. A., and Jurcic, J. G. (2004) Sequential therapy with cytarabine and bismuth-213 (Bi-213)-labeled-HuM195 (anti-CD33) for acute myeloid leukemia (AML) Blood 104, 496a
6. Allen, B. J., Raja, C., Rizvi, S., Li, Y., Tsui, W., Graham, P., Thompson, J. F., Reisfeld, R. A., Kearsley, J., Morgenstern, A., and Apostolidis, C. (2005) Cancer Biol. Ther. 4, 1318-24
7. Kneifel, S., Cordier, D., Good, S., Ionescu, M. C., Ghaffari, A., Hofer, S., Kretzschmar, M., Tolnay, M., Apostolidis, C., Waser, B., Arnold, M., Mueller-Brand, J., Maecke, H. R., Reubi, J. C., and Merlo, A. (2006) Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance P Clin. Cancer Res. 12, 3843-50 (Pubitemid 44000266)
8. Nikula, T. K., McDevitt, M. R., Finn, R. D., Wu, C., Kozak, R. W., Garmasteni, K., Brechbiel, M. W., Curcio, M. J., Pippin, C. G., Tiffany-Jones, L., Geerlings, M. W., Sr, Apostolidis, C., Molinet, R., Geerlings, M. W., Jr, Gansow, O. A., and Scheinberg, D. A. (1999) Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: Pharmacokinetics, bioactivity, toxicity, and chemistry J. Nucl. Med. 40, 166-76 (Pubitemid 29044188)
9. Kumar, K., Magerstadt, M., and Gansow, O. A. (1989) Lead(II) and bismuth(III) complexes of the polyazacycloalkane- N -acetic Acids nota, dota, and teta J. Chem. Soc., Chem. Commun. 145-6
10. Chong, H. S., Lim, S., Baidoo, K. E., Milenic, D. E., Ma, X., Jia, F., Song, H. A., Brechbiel, M. W., and Lewis, M. R. (2008) Synthesis and biological evaluation of a novel decadentate ligand DEPA Bioorg. Med. Chem. Lett. 18, 5792-5
11. Brechbiel, M. W. and Gansow, O. A. (1992) Synthesis of C -functionalized trans-cyclohexyldiethylenetri-aminepenta-acetic acids for labeling of monoclonal antibodies with the bismuth-212-α particle emitter J. Chem. Soc., Perkin. Trans. 1 1173-8
12. Milenic, D. E., Roselli, M., Mirzadeh, S., Pippin, C. G., Gansow, O. A., Colcher, D., Brechbiel, M. W., and Schlom, J. (2001) In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates Cancer Biother. Radiopharm. 16, 133-54
13. Baselga, J. (2001) Phase I and II clinical trials of trastuzumab Ann. Oncol. 12, S49-55
14. Agus, D. B., Bunn, P. A, Jr., Franklin, W., Garcia, M., and Ozols, R. F. (2000) HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer Semin. Oncol. 27, 53-63 (Pubitemid 32172257)
15. Milenic, D. E., Garmestani, K., Brady, E. D., Albert, P. S., Ma, D., Abdulla, A., and Brechbiel, M. W. (2004) Targeting of HER2 antigen for the treatment of disseminated peritoneal disease Clin. Cancer Res. 10, 7834-41 (Pubitemid 39587521)
16. Chong, H. S., Song, H. A., Kang, C. S., Le, T., Sun, X., Dadwal, M., Lee, H. B., Lan, X., Chen, Y., and Dai, A. A highly effective bifunctional ligand for radioimmunotherapy of cancer. Chem. Commun. 2011, not supplied.
17. Brady, E. D., Chong, H. S., Milenic, D. E., and Brechbiel, M. W. (2004) Development of a spectroscopy assay for bifunctional ligand-protein conjugates based on copper Nucl. Med. Biol. 31, 795-802 (Pubitemid 38887762)
18. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) Protein measurement with the folin phenol reagent J. Biol. Chem. 193, 265-75
19. Chappell, L. L., Ma, D., Milenic, D. E., Garmestani, K., Venditto, V., Beitzel, M. P., and Brechbiel, M. W. (2003) Synthesis and evaluation of novel bifunctional chelating agents based on 1,4,7,10-Tetraazacyclododecane- N, N, N, N -Tetraacetic acid for radiolabeling proteins Nucl. Med. Biol. 30, 581-95 (Pubitemid 37289320)
20. 224Ra Int. J. Appl. Instrum. Part A 39, 283-6
21. 225Ac radioimmunotherapeuticals Appl. Radiat. Isot. 57, 841-7
22. Miao, Y, Hylarides, M, Fisher, D. R., Shelton, T., Moore, H., Wester, D. W., Fritzberg, A. R., Winkelmann, C. T., Hoffman, T., and Quinn, T. P. (2005) Melanoma therapy via peptide-targeted {alpha}-radiation Clin. Cancer Res. 11, 5616-21 (Pubitemid 41060840)
23. Milenic, D. E., Garmestani, K., Brady, E. D., Albert, P. S., Ma, D., Abdulla, A., and Brechbiel, M. W. (2005) Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a 212Pb-labeled radioimmunoconjugate targeting HER2 Cancer Biother. Radiopharm. 20, 557-68 (Pubitemid 41619147)
24. 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors Clin. Cancer Res. 14, 3555-61
25. Ballangrud, A. M., Yang, W.-H., Palm, S., Enmon, R., Borchardt, P. E., Pellegrini, V. E., McDevitt, M. R., Scheinberg, D. A., and Sgouros, G. (2004) Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (Herceptin) targeting of breast cancer spheroids: efficacy versus HER2/ neu expression Clin. Cancer Res. 10, 4489-97 (Pubitemid 38878893)
26. 212Pb-labeled monoclonal antibody in the treatment of murine erythroleukemia Int. J. Radiat. Oncol. Biol. Phys. 34, 609-16
27. 212Pb-DOTA Radiochim. Acta. 60, 1-10